Bladder cancer drug trial pulled before starting
NCT ID NCT07342517
First seen Jan 18, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This was a planned Phase 3 study testing a drug called NDV-01 (a slow-release combination of two chemotherapy drugs) for people with a type of bladder cancer that did not respond to standard BCG treatment. The goal was to see if the drug could make the cancer disappear, but the study was withdrawn before enrolling any participants. It was designed for adults whose cancer returned after first-line therapy and who were recommended for bladder removal surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.